Oncology Institute Inc. (TOI)
NASDAQ: TOI
· Real-Time Price · USD
3.04
0.05 (1.67%)
At close: May 23, 2025, 3:59 PM
2.96
-2.47%
After-hours: May 23, 2025, 05:46 PM EDT
Oncology Institute Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Capitated Revenue Revenue | 68.69M | 70.37M | 61.34M | 54.28M |
| Capitated Revenue Revenue Growth | -2.39% | +14.72% | +13.00% | n/a |
| Clinical Research Trials And Other Revenue Revenue | 8.61M | 6.9M | 6.36M | 6.38M |
| Clinical Research Trials And Other Revenue Revenue Growth | +24.83% | +8.58% | -0.38% | n/a |
| Dispensary Revenue Revenue | 179.92M | 103.83M | 79.34M | 72.55M |
| Dispensary Revenue Revenue Growth | +73.27% | +30.87% | +9.36% | n/a |
| Fee For Service Revenue | 136.2M | 143.13M | 105.44M | 69.79M |
| Fee For Service Revenue Growth | -4.85% | +35.74% | +51.09% | n/a |
| Health Care, Patient Service Revenue | 204.88M | 213.5M | 166.78M | 124.07M |
| Health Care, Patient Service Revenue Growth | -4.04% | +28.01% | +34.42% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 25.38M | 24.86M | 26.65M | 27.87M | 28.45M | 28.09M | 28.2M | 28.73M | 28.83M | 29.57M | 31.96M | 28.35M | 29.81M | 48.24M | 12.73M | 11.21M | 11.18M | 41.57M | 148.48K | 8.55M | 8.82M | 8.83M |
| Selling, General, and Administrative Revenue Growth | +2.08% | -6.71% | -4.40% | -2.04% | +1.30% | -0.41% | -1.81% | -0.36% | -2.51% | -7.48% | +12.75% | -4.89% | -38.22% | +278.99% | +13.54% | +0.31% | -73.11% | +27894.50% | -98.26% | -3.12% | -0.13% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |